Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06322875
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-21
First Post:
2024-02-26
Brief Title:
A Clinical Study to Evaluate the Efficacy and Satisfaction of RHC Serum Combined With RHCIII Injection
Sponsor:
DeYi Aesthetic Medical Clinic
Organization:
DeYi Aesthetic Medical Clinic
Study Overview
Official Title:
A Prospective Single-center Randomized Split-face Controlled Single-blind Evaluation Superiority Clinical Trial to Evaluate the Efficacy and Safety of RHCIII for Injection Combined With SkinCeuticals RHC Serum
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of recombinant humanized collagen type III solution for injection combined with SkinCeuticals recombinant humanized collagen RHC serum Participants will be assessed by subjective questionnaire FACE-Q Satisfaction with skinGlobal Aesthetic Improvement Scale et al and some medical instruments VISIAUltrascan UC22 et al
Detailed Description:
With the growth of photoaging and age more people have the appearance of fine lines skin laxity roughness Clinical evidences shown that RHC III injection can effectively improve fine line skin plumpness and firmness to some extent SkinCeutials RHC serum is capable of improving skin plumpness firmness and elasticity and improve rough skin condition
A Prospective single-center randomized split-face controlled single-blind evaluation superior efficacy clinical trial to evaluate the efficacy and safety of recombinant humanized collagen type III solution for injection combined with SkinCeuticals recombinant humanized collagen RHC serum to explore the synergetic effects of injectable integrated skincare in Chinese population
A total of 54 subjects will be enrolled in this study and half of the face of each subject will be randomly assigned 11 to the test side and the control side
The subjects will receive one injection of recombinant type III humanized collagen solution and will be followed up for 12 weeks after injection treatment
Experimental group SkinCeuticals RHC cream and Regular cream twice daily Control group Regular cream twice daily
Participants will be assessed by subjective questionnaire FACE-Q Satisfaction with skinGlobal Aesthetic Improvement Scale et al and some medical instruments VISIAUltrascan UC22 et al
A Prospective single-center randomized split-face controlled single-blind evaluation superior efficacy clinical trial to evaluate the efficacy and safety of recombinant humanized collagen type III solution for injection combined with SkinCeuticals recombinant humanized collagen RHC serum to explore the synergetic effects of injectable integrated skincare in Chinese population
A total of 54 subjects will be enrolled in this study and half of the face of each subject will be randomly assigned 11 to the test side and the control side
The subjects will receive one injection of recombinant type III humanized collagen solution and will be followed up for 12 weeks after injection treatment
Experimental group SkinCeuticals RHC cream and Regular cream twice daily Control group Regular cream twice daily
Participants will be assessed by subjective questionnaire FACE-Q Satisfaction with skinGlobal Aesthetic Improvement Scale et al and some medical instruments VISIAUltrascan UC22 et al
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None